AAAAAA
Results: 1-25/39
Authors:
Harbeck, N
Alt, U
Berger, U
Kruger, A
Thomssen, C
Janicke, F
Hofler, H
Kates, RE
Schmitt, M
Citation: N. Harbeck et al., Prognostic impact of proteolytic factors (Urokinase-Type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy, CLIN CANC R, 7(9), 2001, pp. 2757-2764
Authors:
Schmalfeldt, B
Prechtel, D
Harting, K
Spathe, K
Rutke, S
Konik, E
Fridman, R
Berger, U
Schmitt, M
Kuhn, W
Lengyel, E
Citation: B. Schmalfeldt et al., Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer, CLIN CANC R, 7(8), 2001, pp. 2396-2404
Authors:
Sendler, A
Gilbertz, KP
Becker, I
Mueller, J
Berger, U
Fink, U
van Beuningen, D
Siewert, JR
Citation: A. Sendler et al., Proliferation kinetics and prognosis in gastric cancer after resection, EUR J CANC, 37(13), 2001, pp. 1635-1641
Authors:
Berger, U
Oehme, M
Girardin, L
Citation: U. Berger et al., Quantification of derivatives of bisphenol A diglycidyl ether (BADGE) and novolac glycidyl ether (NOGE) migrated from can coatings into tuna by HPLC/fluorescence and MS detection, FRESEN J AN, 369(2), 2001, pp. 115-123
Authors:
Gaebler, C
Berger, U
Schandelmaier, P
Greitbauer, M
Schauwecker, HH
Applegate, B
Zych, G
Vecsei, V
Citation: C. Gaebler et al., Rates and odds ratios for complications in closed and open tibial fractures treated with unreamed, small diameter tibial nails: A multicenter analysis of 467 cases, J ORTHOP TR, 15(6), 2001, pp. 415-423
Authors:
Hochhaus, A
Lahaye, T
Kreil, S
Berger, U
Metzgeroth, G
Hehlmann, R
Citation: A. Hochhaus et al., Selective inhibition of tyrosine kinases - a new therapeutic principle in oncology, ONKOLOGIE, 24, 2001, pp. 65-71
Authors:
Braumann, O
Greuel, HW
Heitkotter, B
Schneider, HJ
Scholle, W
Schoneberg, U
Berger, U
Citation: O. Braumann et al., Bright steel - tightest tolerances and host surfaces for demanding final products, STAHL EISEN, 121(2), 2001, pp. 61-66
Authors:
Berger, U
Niggl, KH
Reus, B
Citation: U. Berger et al., Theoretical computer science - Logic, semantics and theory of programming - Preface, THEOR COMP, 264(2), 2001, pp. 169-169
Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer
Authors:
Lengyel, E
Schmalfeldt, B
Konik, E
Spathe, K
Harting, K
Fenn, A
Berger, U
Fridman, R
Schmitt, M
Prechtel, D
Kuhn, W
Citation: E. Lengyel et al., Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer, GYNECOL ONC, 82(2), 2001, pp. 291-298
Authors:
Hochhaus, A
Kreil, S
Corbin, A
La Rosee, P
Lahaye, T
Berger, U
Cross, NCP
Linkesch, W
Druker, BJ
Hehlmann, R
Citation: A. Hochhaus et al., Roots of clinical resistance to STI-571 cancer therapy, SCIENCE, 293(5538), 2001, pp. NIL_1-NIL_3
Authors:
Prechtel, D
Harbeck, N
Berger, U
Hofler, H
Werenskiold, AK
Citation: D. Prechtel et al., Clinical relevance of T1-S, an oncogene-inducible, secreted glycoprotein of the immunoglobulin superfamily, in node-negative breast cancer, LAB INV, 81(2), 2001, pp. 159-165
Authors:
de la Fuente, J
Merx, K
Steer, EJ
Muller, M
Szydlo, RM
Maywald, O
Berger, U
Hehlmann, R
Goldman, JM
Cross, NCP
Melo, JV
Hochhaus, A
Citation: J. De La Fuente et al., ABL-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia, BLOOD, 98(9), 2001, pp. 2879-2880
Authors:
Ulm, K
Nekarda, H
Gerein, P
Berger, U
Citation: K. Ulm et al., Statistical methods to identify prognostic factors, HANDBOOK OF STATISTICS IN CLINICAL ONCOLOGY, 2001, pp. 379-395
Authors:
Berger, U
Oehme, M
Citation: U. Berger et M. Oehme, Identification of derivatives of bisphenol A diglycidyl ether and novolac glycidyl ether in can coatings by liquid chromatography/ion trap mass spectrometry, J AOAC INT, 83(6), 2000, pp. 1367-1376
Authors:
Hehlmann, R
Hochhaus, A
Berger, U
Reiter, A
Citation: R. Hehlmann et al., Current trends in the management of chronic myelogenous leukemia, ANN HEMATOL, 79(7), 2000, pp. 345-354
Authors:
Lengfelder, E
Berger, U
Hehlmann, R
Citation: E. Lengfelder et al., Interferon alpha in the treatment of polycythemia vera, ANN HEMATOL, 79(3), 2000, pp. 103-109
Authors:
Hochhaus, A
Weisser, A
La Rosee, P
Emig, M
Muller, MC
Saussele, S
Reiter, A
Kuhn, C
Berger, U
Hehlmann, R
Cross, NCP
Citation: A. Hochhaus et al., Detection and quantification of residual disease in chronic myelogenous leukemia, LEUKEMIA, 14(6), 2000, pp. 998-1005
Authors:
Harbeck, N
Alt, U
Berger, U
Kates, R
Kruger, A
Thomssen, C
Janicke, F
Graeff, H
Schmitt, M
Citation: N. Harbeck et al., Long-term follow-up confirms prognostic impact of PAI-1 and cathepsin D and L in primary breast cancer, INT J B MAR, 15(1), 2000, pp. 79-83
Authors:
Saint-Paul, U
Zuanon, J
Correa, MAV
Garcia, M
Fabre, NN
Berger, U
Junk, WJ
Citation: U. Saint-paul et al., Fish communities in central Amazonian white- and blackwater floodplains, ENV BIOL F, 57(3), 2000, pp. 235-250
Authors:
Nettelbeck, HJ
Berger, U
Citation: Hj. Nettelbeck et U. Berger, The cold rolling committee and technical developments of cold rolling and surface treatment (vol 120, pg 43, 2000), STAHL EISEN, 120(2), 2000, pp. 25-25
Authors:
Nettelbeck, HJ
Berger, U
Citation: Hj. Nettelbeck et U. Berger, The cold rolling committee and technical developments of cold rolling and surface treatment, STAHL EISEN, 120(1), 2000, pp. 43-50
Authors:
Berger, U
Hildenbrandt, H
Citation: U. Berger et H. Hildenbrandt, A new approach to spatially explicit modelling of forest dynamics: Spacing, ageing and neighbourhood competition of mangrove trees, ECOL MODEL, 132(3), 2000, pp. 287-302
Authors:
Heyer, J
Berger, U
Citation: J. Heyer et U. Berger, Methane emission from the coastal area in the southern Baltic Sea, EST COAST S, 51(1), 2000, pp. 13-30
Authors:
Mummendey, A
Otten, S
Berger, U
Kessler, T
Citation: A. Mummendey et al., Positive-negative asymmetry in social discrimination: Valence of evaluation and salience of categorization, PERS SOC PS, 26(10), 2000, pp. 1258-1270
Authors:
Hochhaus, A
Reiter, A
Saussele, S
Reichert, A
Emig, M
Kaeda, J
Schultheis, B
Berger, U
Shepherd, PCA
Allan, NC
Hehlmann, R
Goldman, JM
Cross, NCP
Citation: A. Hochhaus et al., Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission, BLOOD, 95(1), 2000, pp. 62-66